In a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump, Valeritas (NSDQ:VLRX) reported this week that use of its device led to a 44% reduction in total daily insulin dose per patient. A drastic cut to a patient’s daily insulin dose and improvement to their blood sugar levels […]
Clinical Trials
GI Dynamics touts weight loss, lowered HbA1c in EndoBarrier meta-analysis
GI Dynamics (ASX:GID) yesterday released data from a meta-analysis of its EndoBarrier device, touting improved glycemic control in patients with type 2 diabetes and obesity. Data from the meta-analysis study was presented at the Digestive Disease Week meeting in Chicago. The EndoBarrier device from the Lexington, Mass.-based company is a plastic gut sleeve designed to prevent the absorption of […]
Glaukos touts economic savings in dual iStent study
Glaukos (NYSE:GKOS) today touted data from an economic analysis of elevated intraocular pressure treatments in open-angle glaucoma patients, which reported low cost associated with the use of its iStent devices. The economic analysis study aimed to analyze direct cost for 3 treatment options for treating patients with elevated IOP open-angle glaucoma, including selective laser trabeculoplasty, topical […]
United Orthopedic launches 7-year U2 knee system trial
United Orthopedic Corp. said today it launched a new trial of its U2 total knee arthroplasty system and has enrolled the 1st patient in the trial. In the study, the Irvine, Calif.-based company will examine short and long term clinical performance and implant survivorship in patients undergoing TKA procedures with its U2 unit. “We were extremely […]
Fractyl Labs launches Revita DMR diabetic treatment study
Fractyl Laboratories said today it launched the Revita-2 clinical trial of its Revita DMR procedure in orally-treated type 2 diabetes patients with poorly controlled disease. The company said that it has enrolled the 1st patient in the trial at a European center participating in the study. The Revita DMR is a minimally invasive procedure designed to […]
Novartis’ Ultibro Breezhaler tops corticosteroid for COPD in head-to-head study
Novartis (NYSE:NVS) said today that a new analysis of its head-to-head Flame trial showed that inhaled corticosteroids may not be necessary in some chronic obstructive pulmonary disease patients with high blood eosiophil counts. The data demonstrated that the company’s Ultibro Breezhaler provided better or similar benefits compared to Seretide, an inhaled corticosteroid, in COPD patients […]
Symic Bio raises $30m for peripheral vein graft failure therapy
Symic Bio said yesterday that it raised $30 million in a Series B financing round, led by existing investors and HEDA Ventures. Funds from the round are slated to support the company’s clinical programs, including a drug designed to prevent peripheral vein graft failure, SB-030, and a therapy for pain management of osteoarthritis of the knee, […]
Anika touts Phase III data for Cingal knee therapy
Anika Therapeutics (NSDQ:ANIK) touted data today from a Phase III trial for its Cingal hyaluronic acid-corticosteroid combination viscosupplement as a treatment for osteoarthritis-related knee pain. The data showed that treatment with Cingal yielded better immediate and short-term pain relief compared to hyaluronic acid alone and better pain and stiffness relief through 26 weeks compared to saline. […]
Philips, ResMed tout collaborative home ventilation therapy COPD study results
Royal Philips (NYSE:PHG) and ResMed (NYSE:RMD) today touted results from a collaboratively-supported clinical trial exploring the use of home noninvasive ventilation with oxygen therapy on patients with chronic obstructive pulmonary disorder, which indicated improved survivability and prolonged time to readmission. Results from the study were published today in the Journal of the American Medical Association. “Patients […]
EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard
Abbott’s (NYSE:ABT) bioresorbable scaffold has been plagued with a myriad of troubling data, including a study that showed that the device is associated with an increase in thrombosis and target lesion failure. In April, Abbott pulled the stent from European markets. In response to widespread criticism of the technology, the EuroPCR team released a statement this […]
ViaCyte looks to cell replacement therapy to cure Type I diabetes
ViaCyte said today that it will begin clinical trials of its novel islet cell replacement therapy in development as a potential cure for Type I diabetes, after landing regulatory wins from the FDA and Health Canada. The company’s PEC-Direct candidate delivers stem cell-derived pancreatic progenitor cells in a device that is designed to enable direct […]